See more : Diamyd Medical AB (publ) (DMYD-B.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Vapotherm, Inc. (VAPO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vapotherm, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Lonza Group AG (0QNO.L) Income Statement Analysis – Financial Results
- Adtalem Global Education Inc. (ATGE) Income Statement Analysis – Financial Results
- Carasso Motors Ltd. (CRSO.TA) Income Statement Analysis – Financial Results
- Lincoln National Corporation (LNC) Income Statement Analysis – Financial Results
- Hongli Zhihui Group Co.,Ltd. (300219.SZ) Income Statement Analysis – Financial Results
Vapotherm, Inc. (VAPO)
About Vapotherm, Inc.
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol medication; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 68.67M | 66.80M | 113.29M | 125.73M | 48.10M | 42.38M | 35.60M | 30.12M |
| Cost of Revenue | 40.39M | 49.56M | 60.10M | 62.69M | 26.79M | 25.61M | 22.36M | 20.18M |
| Gross Profit | 28.28M | 17.24M | 53.19M | 63.05M | 21.31M | 16.77M | 13.24M | 9.94M |
| Gross Profit Ratio | 41.19% | 25.81% | 46.95% | 50.14% | 44.30% | 39.58% | 37.19% | 33.00% |
| Research & Development | 14.21M | 20.80M | 18.41M | 16.96M | 13.38M | 8.77M | 7.57M | 6.21M |
| General & Administrative | 19.26M | 27.80M | 31.38M | 24.04M | 18.41M | 11.19M | 8.02M | 5.94M |
| Selling & Marketing | 32.55M | 46.09M | 60.14M | 65.07M | 37.69M | 33.93M | 26.22M | 20.03M |
| SG&A | 51.81M | 73.89M | 91.52M | 89.10M | 56.10M | 45.11M | 34.24M | 25.97M |
| Other Expenses | 0.00 | 0.00 | 18.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.03M | 94.69M | 109.93M | 106.06M | 69.48M | 53.88M | 41.81M | 32.18M |
| Cost & Expenses | 106.41M | 144.25M | 170.03M | 168.75M | 96.27M | 79.49M | 64.17M | 52.36M |
| Interest Income | 78.00K | 139.00K | 91.00K | 257.00K | 860.00K | 118.00K | 3.00K | 8.00K |
| Interest Expense | 18.73M | 11.64M | 2.60M | 4.71M | 5.10M | 3.06M | 2.23M | 716.00K |
| Depreciation & Amortization | 4.98M | 5.18M | 5.65M | 4.77M | 3.08M | 2.17M | 1.53M | 1.34M |
| EBITDA | -34.36M | -100.39M | -52.40M | -43.01M | -44.89M | -37.23M | -27.24M | -20.89M |
| EBITDA Ratio | -47.60% | -107.97% | -45.00% | -30.21% | -91.94% | -82.18% | -75.94% | -69.36% |
| Operating Income | -39.08M | -77.45M | -56.74M | -43.01M | -48.16M | -37.23M | -28.87M | -22.22M |
| Operating Income Ratio | -56.91% | -115.94% | -50.08% | -34.21% | -100.12% | -87.86% | -81.11% | -73.78% |
| Total Other Income/Expenses | -18.99M | -12.86M | -2.71M | -8.49M | -3.04M | -5.24M | -2.44M | -849.00K |
| Income Before Tax | -58.07M | -113.25M | -59.88M | -51.50M | -51.21M | -42.47M | -31.01M | -23.07M |
| Income Before Tax Ratio | -84.56% | -169.53% | -52.85% | -40.96% | -106.45% | -100.21% | -87.10% | -76.60% |
| Income Tax Expense | 126.00K | 11.00K | -76.00K | 4.71M | -146.00K | 2.41M | 206.00K | 127.00K |
| Net Income | -58.19M | -113.26M | -59.80M | -56.21M | -51.06M | -42.47M | -31.01M | -23.07M |
| Net Income Ratio | -84.74% | -169.55% | -52.78% | -44.71% | -106.14% | -100.21% | -87.10% | -76.60% |
| EPS | -9.64 | -33.89 | -18.48 | -18.88 | -21.96 | -116.95 | -357.12 | -394.95 |
| EPS Diluted | -9.64 | -33.89 | -18.44 | -18.88 | -21.96 | -116.95 | -357.12 | -394.95 |
| Weighted Avg Shares Out | 6.04M | 3.34M | 3.24M | 2.98M | 2.33M | 363.14K | 86.82K | 58.42K |
| Weighted Avg Shares Out (Dil) | 6.04M | 3.34M | 3.24M | 2.98M | 2.33M | 363.14K | 86.82K | 58.42K |
Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Vapotherm Announces Suspension of NYSE Listing Common Stock Expected to Begin Trading Promptly on OTCQX
NYSE to Commence Delisting Proceedings Against Vapotherm, Inc. (VAPO)
Vapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQX
Vapotherm Educates over 8,000 Clinicians in Respiratory Care Month
Vapotherm, Inc. (VAPO) Q3 2023 Earnings Call Transcript
Vapotherm Reports Third Quarter 2023 Financial Results
3 Stocks Set to Rocket When the Bears Get Short-Squeezed
Vapotherm To Report Third Quarter 2023 Financial Results
Computational Fluid Dynamics (CFD) modeling further distinguishes Vapotherm High Velocity Therapy from generic high flow cannulas
Source: https://incomestatements.info
Category: Stock Reports